Ocean Biomedical, Inc. (OCEA) presents a deeply negative liquidation posture as of March 31, 2025. Total assets are $1.6 million against total liabilities of $94.0 million, producing a stockholders' deficit of $92.4 million. Under liquidation haircuts, the asset side recovers essentially nothing: total assets consist of $0.8 million restricted cash held in escrow (100% recovery = $0.8 million), $0.7 million prepaid expenses (negligible recovery), and $90,000 in subsidiary investments (0% recovery as intangible). Applying standard haircuts yields roughly $0.8 million in recoverable asset value. Against $94.0 million in face-value liabilities — including $26.6 million current liabilities, $9.4 million short-term loans (Second Street Capital and McKra), $4.4 million fair-value convertible notes (Ayrton 2024 facility), and $67.4 million in non-current liabilities dominated by the Backstop Put Option Liability and Fixed Maturity Consideration carried at fair value — equity recovery is effectively negative $93 million. The MFFAIS CLV/LLV/OLV of negative $23.4 million likely reflects only the most liquid components and understates the full liquidation deficit when all non-current liabilities are included at face. The company has zero unrestricted cash as of the period end; $0.8 million restricted cash is held in escrow and is not freely available. The company explicitly discloses going concern doubt. A subsequent event of material impact: Nasdaq notified OCEA on April 22, 2025 that common stock would be delisted effective April 24, 2025, with a Form 25 filing pending. Post-period, the Ayrton investor converted $1.2 million of convertible notes into 66.4 million shares, further diluting equity holders. Off-balance-sheet exposures include $16.9 million in contingent management compensation and $1.0 million in contingent vendor payments, both contingent on a first cumulative capital raise of $50 million — not probable but material if triggered. Filing discusses the Backstop Put Option Liability and Fixed Maturity Consideration extensively in MD&A but these are carried as fair-value liabilities on the balance sheet, not separately tagged in XBRL at the individual liability level. Disclosure controls were assessed as not effective as of March 31, 2025, with identified material weaknesses in staffing and review of third-party valuation deliverables for convertible debt and warrant liabilities — introducing model risk into the $72.0 million fair-value liability stack.
▼ Community Notes